Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Benign prostatic hyperplasia (BPH) also known as benign prostatic hypertrophy is characterized by the unusual propagation of the prostatic cells, which causes difficulties like urinary retention and infections of the urinary tract. It is most common among the aging men population, primarily driving this market. On the basis of geographical analysis, the North American region is expected to retain its dominance in this market owing to better healthcare infrastructure, high healthcare expenditure on urological disorders, increased awareness in the society increasing the outpatients center and hospitals visits.
The report details the trend, potential and market size of Benign Prostatic Hyperplasia market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Benign Prostatic Hyperplasiamarket, defines the market attractiveness level of Benign Prostatic Hyperplasia market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Benign Prostatic Hyperplasia industry, describes the types of Benign Prostatic Hyperplasia market, the applications of major players and the market size, and deeply analyzes the current situation of the global Benign Prostatic Hyperplasia market and the development prospects and opportunities of Benign Prostatic Hyperplasia industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Benign Prostatic Hyperplasia market in Chapter 13.
By Player:
Pfizer
Astellas Pharma
TEVA
Merck
Mylan
Abbott
Allergan
Eli Lilly
Novartis
Sanofi
GlaxoSmithKline
By Type:
Drug Therapy
Dialysis
Other
By End-User:
Hospitals
Clinics
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Benign Prostatic Hyperplasia Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Benign Prostatic Hyperplasia Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Benign Prostatic Hyperplasia Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Benign Prostatic Hyperplasia Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Benign Prostatic Hyperplasia Market Analysis and Outlook to 2022
-
7.1 Global Benign Prostatic Hyperplasia Consumption (2017-2022)
-
7.2 United States Benign Prostatic Hyperplasia Consumption (2017-2022)
-
7.3 Europe Benign Prostatic Hyperplasia Consumption (2017-2022)
-
7.4 China Benign Prostatic Hyperplasia Consumption (2017-2022)
-
7.5 Japan Benign Prostatic Hyperplasia Consumption (2017-2022)
-
7.6 India Benign Prostatic Hyperplasia Consumption (2017-2022)
-
7.7 South Korea Benign Prostatic Hyperplasia Consumption (2017-2022)
8 Region and Country-wise Benign Prostatic Hyperplasia Market Analysis and Outlook to 2028
-
8.1 Global Benign Prostatic Hyperplasia Consumption Forecast (2022-2028)
-
8.2 United States Benign Prostatic Hyperplasia Consumption Forecast (2022-2028)
-
8.3 Europe Benign Prostatic Hyperplasia Consumption Forecast (2022-2028)
-
8.4 China Benign Prostatic Hyperplasia Consumption Forecast (2022-2028)
-
8.5 Japan Benign Prostatic Hyperplasia Consumption Forecast (2022-2028)
-
8.6 India Benign Prostatic Hyperplasia Consumption Forecast (2022-2028)
-
8.7 South Korea Benign Prostatic Hyperplasia Consumption Forecast (2022-2028)
9 Global Benign Prostatic Hyperplasia Market Outlook by Types and Applications to 2022
-
9.1 Global Benign Prostatic Hyperplasia Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Drug Therapy Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Dialysis Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Other Consumption and Growth Rate (2017-2022)
-
9.2 Global Benign Prostatic Hyperplasia Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)
10 Global Benign Prostatic Hyperplasia Market Outlook by Types and Applications to 2028
-
10.1 Global Benign Prostatic Hyperplasia Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Drug Therapy Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Dialysis Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Other Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Benign Prostatic Hyperplasia Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)
11 Global Benign Prostatic Hyperplasia Import and Export Analysis (Top 5 Countries)
-
11.1 Global Benign Prostatic Hyperplasia Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Benign Prostatic Hyperplasia Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Benign Prostatic Hyperplasia Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Benign Prostatic Hyperplasia Market Competitive Analysis
-
14.1 Pfizer
-
14.1.1 Pfizer Company Details
-
14.1.2 Pfizer Benign Prostatic Hyperplasia Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Pfizer Benign Prostatic Hyperplasia Product and Service
-
14.2 Astellas Pharma
-
14.2.1 Astellas Pharma Company Details
-
14.2.2 Astellas Pharma Benign Prostatic Hyperplasia Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Astellas Pharma Benign Prostatic Hyperplasia Product and Service
-
14.3 TEVA
-
14.3.1 TEVA Company Details
-
14.3.2 TEVA Benign Prostatic Hyperplasia Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 TEVA Benign Prostatic Hyperplasia Product and Service
-
14.4 Merck
-
14.4.1 Merck Company Details
-
14.4.2 Merck Benign Prostatic Hyperplasia Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Merck Benign Prostatic Hyperplasia Product and Service
-
14.5 Mylan
-
14.5.1 Mylan Company Details
-
14.5.2 Mylan Benign Prostatic Hyperplasia Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Mylan Benign Prostatic Hyperplasia Product and Service
-
14.6 Abbott
-
14.6.1 Abbott Company Details
-
14.6.2 Abbott Benign Prostatic Hyperplasia Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Abbott Benign Prostatic Hyperplasia Product and Service
-
14.7 Allergan
-
14.7.1 Allergan Company Details
-
14.7.2 Allergan Benign Prostatic Hyperplasia Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Allergan Benign Prostatic Hyperplasia Product and Service
-
14.8 Eli Lilly
-
14.8.1 Eli Lilly Company Details
-
14.8.2 Eli Lilly Benign Prostatic Hyperplasia Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 Eli Lilly Benign Prostatic Hyperplasia Product and Service
-
14.9 Novartis
-
14.9.1 Novartis Company Details
-
14.9.2 Novartis Benign Prostatic Hyperplasia Sales, Price, Value and Gross Profit (2017-2022)
-
14.9.3 Novartis Benign Prostatic Hyperplasia Product and Service
-
14.10 Sanofi
-
14.10.1 Sanofi Company Details
-
14.10.2 Sanofi Benign Prostatic Hyperplasia Sales, Price, Value and Gross Profit (2017-2022)
-
14.10.3 Sanofi Benign Prostatic Hyperplasia Product and Service
-
14.11 GlaxoSmithKline
-
14.11.1 GlaxoSmithKline Company Details
-
14.11.2 GlaxoSmithKline Benign Prostatic Hyperplasia Sales, Price, Value and Gross Profit (2017-2022)
-
14.11.3 GlaxoSmithKline Benign Prostatic Hyperplasia Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Benign Prostatic Hyperplasia
-
Figure Benign Prostatic Hyperplasia Picture
-
Table Global Benign Prostatic Hyperplasia Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Benign Prostatic Hyperplasia Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Benign Prostatic Hyperplasia Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Benign Prostatic Hyperplasia Consumption by Country (2017-2022)
-
Figure United States Benign Prostatic Hyperplasia Consumption and Growth Rate (2017-2022)
-
Table Europe Benign Prostatic Hyperplasia Consumption and Growth Rate (2017-2022)
-
Figure China Benign Prostatic Hyperplasia Consumption and Growth Rate (2017-2022)
-
Figure Japan Benign Prostatic Hyperplasia Consumption and Growth Rate (2017-2022)
-
Figure India Benign Prostatic Hyperplasia Consumption and Growth Rate (2017-2022)
-
Figure South Korea Benign Prostatic Hyperplasia Consumption and Growth Rate (2017-2022)
-
Figure Global Benign Prostatic Hyperplasia Consumption Forecast by Country (2022-2028)
-
Figure United States Benign Prostatic Hyperplasia Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Benign Prostatic Hyperplasia Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Benign Prostatic Hyperplasia Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Benign Prostatic Hyperplasia Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Benign Prostatic Hyperplasia Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Benign Prostatic Hyperplasia Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Drug Therapy Consumption and Growth Rate (2017-2022)
-
Figure Global Dialysis Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global Hospitals Consumption and Growth Rate (2017-2022)
-
Figure Global Clinics Consumption and Growth Rate (2017-2022)
-
Figure Global Drug Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Dialysis Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Benign Prostatic Hyperplasia Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Benign Prostatic Hyperplasia Export by Region (Top 5 Countries) (2017-2028)
-
Table Pfizer (Foundation Year, Company Profile and etc.)
-
Table Pfizer Benign Prostatic Hyperplasia Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Benign Prostatic Hyperplasia Product and Service
-
Table Astellas Pharma (Foundation Year, Company Profile and etc.)
-
Table Astellas Pharma Benign Prostatic Hyperplasia Sales, Price, Value and Gross Profit (2017-2022)
-
Table Astellas Pharma Benign Prostatic Hyperplasia Product and Service
-
Table TEVA (Foundation Year, Company Profile and etc.)
-
Table TEVA Benign Prostatic Hyperplasia Sales, Price, Value and Gross Profit (2017-2022)
-
Table TEVA Benign Prostatic Hyperplasia Product and Service
-
Table Merck (Foundation Year, Company Profile and etc.)
-
Table Merck Benign Prostatic Hyperplasia Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck Benign Prostatic Hyperplasia Product and Service
-
Table Mylan (Foundation Year, Company Profile and etc.)
-
Table Mylan Benign Prostatic Hyperplasia Sales, Price, Value and Gross Profit (2017-2022)
-
Table Mylan Benign Prostatic Hyperplasia Product and Service
-
Table Abbott (Foundation Year, Company Profile and etc.)
-
Table Abbott Benign Prostatic Hyperplasia Sales, Price, Value and Gross Profit (2017-2022)
-
Table Abbott Benign Prostatic Hyperplasia Product and Service
-
Table Allergan (Foundation Year, Company Profile and etc.)
-
Table Allergan Benign Prostatic Hyperplasia Sales, Price, Value and Gross Profit (2017-2022)
-
Table Allergan Benign Prostatic Hyperplasia Product and Service
-
Table Eli Lilly (Foundation Year, Company Profile and etc.)
-
Table Eli Lilly Benign Prostatic Hyperplasia Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eli Lilly Benign Prostatic Hyperplasia Product and Service
-
Table Novartis (Foundation Year, Company Profile and etc.)
-
Table Novartis Benign Prostatic Hyperplasia Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Benign Prostatic Hyperplasia Product and Service
-
Table Sanofi (Foundation Year, Company Profile and etc.)
-
Table Sanofi Benign Prostatic Hyperplasia Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanofi Benign Prostatic Hyperplasia Product and Service
-
Table GlaxoSmithKline (Foundation Year, Company Profile and etc.)
-
Table GlaxoSmithKline Benign Prostatic Hyperplasia Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline Benign Prostatic Hyperplasia Product and Service
-
